Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European organisation for research and treatment of cancer (EORTC) trial 30891

Journal of Clinical Oncology

Volumn 24, Issue 12, 2006, Pages 1868-1876

  Studer, Urs E ^a   Whelan, Peter ^b   Albrecht, Walter ^b   Casselman, Jacques ^b   De Reijke, Theo ^b   Hauri, Dieter ^b   Loidl, Wolfgang ^b   Isorna, Santiago ^b   Sundaram, Subramanian K ^b   Debois, Muriel ^b   Collette, Laurence ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BUSERELIN; CYPROTERONE ACETATE; HORMONE; ANTIANDROGEN;

ADULT; AGED; ARTICLE; CANCER RESEARCH; CANCER STAGING; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSTATE TUMOR; SURVIVAL; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33646360629     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.7423     Document Type: Article

References (17)

1. Harmer MH: TNM Classifications. Geneva, Switzerland, UICC (Union International Contra Cancer), 1978
2. Klign JG, de Voogt HJ, Schroeder FH, et al: Combined treatment with buserelin and cyproterone in metastatic prostatic carcinoma. Lancet 2:493, 1985
3. Thompson IM, Zeidman EJ, Rodriguez FR: Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 144:1479-1480, 1990
4. Arduino LJ, Bailar JC, Becker LE, et al: Carcinoma in the prostate: Treatment comparisons. J Urol 98:516-522, 1967
5. Byar DP: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32:1126-1130, 1973
6. The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the medical research council trial. Br J Urol 79:235-246, 1997
7. Kirk D. Immediate vs. deferred hormone treatment for prostate cancer: How safe is androgen deprivation? Br J Urol 86(suppl 3):S220, 2000
8. Studer UE, Hauri D, Hanselmann S, et al: Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: Results of the randomized trial SAKK 08/88. J Clin Oncol 22:4109-4118, 2004
9. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavourable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15:1013-1021, 1997
10. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
11. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 360:103-106, 2002
12. Pilepich MV, Winter K, John MJ, et al: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243-1252, 2001
13. Laverdiere J, Gomez JL, Cusan L, et al: Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37:245-246, 1997
14. D'Amico AV, Manola J, Loffredo M, et al: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292:864-866, 2004
15. Messing EM, Manola J, Sarosdy M, et al: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788, 1999
16. Iversen P, Johansson JE, Lodding P, et al: Bicalutamide (150mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median follow up from the Scandinavian Prostate Cancer Group Study Number 6 J Urol 172: 1871-1876, 2004
17. Salminen EK, Portin RI, Koskinen A, et al: Associations between serum testosterone fall and cognitive function on prostate cancer patients. Clin Cancer Res 10:7575-7582, 2004